{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:36:24Z","timestamp":1776699384394,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013352","name":"Tow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:37:21Z","timestamp":1739993841000},"page":"590-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-Related Quality of Life in Patients With Relapsed\/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial"],"prefix":"10.1016","volume":"25","author":[{"given":"Katja","family":"Weisel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6600-8838","authenticated-orcid":false,"given":"Mihaela","family":"Talpes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0522-4961","authenticated-orcid":false,"given":"Istvan","family":"Majer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2025.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.02.005_bib0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-018-0163-7","article-title":"Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome","volume":"8","author":"Paquin","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2025.02.005_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.02.005_bib0004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.005_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10245","key":"10.1016\/j.clml.2025.02.005_bib0006","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2025.02.005_bib0007","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.02.005_bib0008","doi-asserted-by":"crossref","first-page":"e3258","DOI":"10.1002\/hon.3258","article-title":"Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed\/refractory multiple myeloma: long-term outcomes in the phase 3 IKEMA study","volume":"42","author":"Facon","year":"2024","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.02.005_bib0009","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"CASTOR investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.02.005_bib0010","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"10.1016\/j.clml.2025.02.005_bib0011","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S2152-2650(21)02318-1","article-title":"Comparison of efficacy outcomes for carfilzomib plus dexamethasone and Daratumumab (KdD) versus pomalidomide plus bortezomib and dexamethasone (PVd) and d-Pd in relapsed or refractory multiple myeloma","volume":"21","author":"Chari","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.02.005_bib0012","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/10428194.2022.2047962","article-title":"Carfilzomib 56 mg\/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with 8 cycles of bortezomib and dexamethasone (DVd); a matching-adjusted indirect treatment comparison","volume":"63","author":"Weisel","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2025.02.005_bib0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428194.2023.2300051","article-title":"Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed\/refractory multiple myeloma: an indirect treatment comparison","volume":"65","author":"Weisel","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2025.02.005_bib0014","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1080\/10428194.2021.1941927","article-title":"Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma","volume":"62","author":"Siegel","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.02.005_bib0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2025.02.005_bib0016","series-title":"The EORTC QLQ-C30 Scoring Manual","article-title":"on behalf of the EORTC Quality of Life Group","author":"Fayers","year":"2001"},{"key":"10.1016\/j.clml.2025.02.005_bib0017","year":"2019","journal-title":"EQ-5D-5L user guide"},{"key":"10.1016\/j.clml.2025.02.005_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"on behalf of the EORTC Quality of Life Group. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2025.02.005_bib0019","unstructured":"Scott NW, Fayers PM, Aaronson NK, et al. . EORTC QLQ-C30 reference values: this manual presents reference data for the QLQ-C30 based upon data provided by EORTC Quality of Life Group Members and other users of the QLQ-C30. 2008. Accessed September 6, 2024. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf."},{"issue":"1","key":"10.1016\/j.clml.2025.02.005_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.02.005_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.HS9.0000846500.86746.52","article-title":"P907: carfilzomib, dexamethasone, and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): frailty subgroup analysis of the CANDOR study","volume":"6","author":"Quach","year":"2022","journal-title":"Hemasphere"},{"issue":"24","key":"10.1016\/j.clml.2025.02.005_bib0022","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/cancers15245764","article-title":"European Hematology Association Specialized Working Group on Quality of Life and symptoms. Guidelines for the use and reporting of patient-reported outcomes in multiple myeloma clinical trials","volume":"15","author":"Laane","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2025.02.005_bib0023","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-reported outcomes in randomized controlled trials of patients with multiple myeloma: a systematic literature review of studies published between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2025.02.005_bib0024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26480","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone \u00b1 subcutaneous daratumumab: patient-reported outcomes from the APOLLO trial","volume":"97","author":"Terpos","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.02.005_bib0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17321","article-title":"Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial","volume":"193","author":"Hungria","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.005_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.17435","article-title":"Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial","volume":"194","author":"Plesner","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:24Z","timestamp":1762600644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025000679"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life in Patients With Relapsed\/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Amgen Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}